article thumbnail

New cell engineering partnership to accelerate biopharma innovation 

Drug Discovery World

Mekonos, a company working towards cell engineering on a chip, has entered into a partnership agreement with Accelerated Bio to codevelop a new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.

article thumbnail

World’s first engineered B cell therapy enters human trials

Drug Discovery World

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Immusoft is advancing the world’s first engineered B cell therapy, which may have significant impact for patients with this rare disease and potentially many others.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Successful clinical trial for re-engineered Covid vaccine 

Drug Discovery World

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The post Successful clinical trial for re-engineered Covid vaccine appeared first on Drug Discovery World (DDW).

article thumbnail

Genetically engineered dendritic cells enhance lung cancer therapy

Drug Discovery World

A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

article thumbnail

A new paradigm for protein engineering 

Drug Discovery World

Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials. And imagine each execution costs $1000.

article thumbnail

Utilising engineered peptides for immunotherapy

Drug Target Review

What potential therapeutic advantages do the engineered cationic polypeptides offer in the context of generating antitumour immune responses? The engineered polypeptides were able to re-modulate tumour microenvironments towards an immune-activating mode, thereby improving the therapeutic potency of immune checkpoint blockade in solid tumours.

article thumbnail

Desktop DNA synthesis could ‘revolutionise’ engineering biology

Drug Discovery World

The first DNA synthesised using Evonetix’s semiconductor chip technology has been delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge.

DNA 130